Upgraded ³ÉÈËBÕ¾ EMPOWER Laser Portfolio and New Generation Flexible Ureteroscopes with DuraBend Technology Showcased
CENTER VALLEY, Pa., (May 2, 2019) – ³ÉÈËBÕ¾, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, will showcase its complete urological portfolio at the American Urological Association (AUA) 2019 Annual Meeting in Chicago. Products featured at AUA will include the URF-V3 flexible uretero-reno videoscope and the URF-P7 uretero-reno fiberscope, as well as an expanded ³ÉÈËBÕ¾ EMPOWER complete laser portfolio offering higher frequency for greater dusting capability with stabilization mode.
As an AUA 2019 Platinum Sponsor, ³ÉÈËBÕ¾ proudly highlights its role as a complete urology provider with a portfolio of products that enable physicians to detect, diagnose and treat upper- and lower-tract urological disorders and diseases. Among the products on display will be those designed for the effective detection and treatment of stones, BPH, and bladder tumors, which include:
- ³ÉÈËBÕ¾ EMPOWERâ„¢ 100
An upgrade to the ³ÉÈËBÕ¾ EMPOWER laser portfolio offers full-range capabilities in Ho:YAG lithotripsy for dusting, fragmentation, soft tissue ablation, and enucleation. ³ÉÈËBÕ¾ EMPOWER offers greater efficiency with higher hertz, in addition to offering customizable user settings. The ³ÉÈËBÕ¾ EMPOWER Stabilization mode reduces retropulsion effect by producing a vapor tunnel path to the stone in order to stabilize the stone and limit retropulsion of the stone.* - URF-V3 Flexible Uretero-reno Videoscope and URF-P7 Uretero-reno Fiberscope
The URF-V3 and URF-P7 offer a super-slim profile body and new passive bending section technology for maneuverability and durability during procedures. ³ÉÈËBվ’ unique insertion-tube design, now with DuraBend, uses materials in four different stiffness degrees (from extra stiff to soft) within the insertion section, to reduce stress on the bending section during insertion in the narrow renal pelvis. Both the videoscope and fiberscope provide a high-resolution image that aids physicians in stone treatment as well as lesion detection. With Narrow Band Imaging (NBI) capability, physicians have greater visibility of vessel structures, which can provide substantial help identifying tumors in the urinary tract.
The ³ÉÈËBÕ¾ sponsorship reflects the company’s ongoing support of high-quality urologist training and cooperation with leading experts in this field, which AUA recognized last year by honoring ³ÉÈËBÕ¾ with the 2018 AUA Health Science Award. At AUA 2019, ³ÉÈËBÕ¾ is furthering its support of urologist education by distributing complimentary copies of the AUA Guidelines-at-a-Glance compendium book to all attendees.
³ÉÈËBÕ¾ also offers physicians and residents opportunities to test their capabilities and hone their skills with NBI Virtual Reality and Flex-Catch Baskets during the ³ÉÈËBÕ¾ Skills Challenge sessions in booth #4016. Additional hands-on opportunities with the ³ÉÈËBÕ¾ EMPOWER H100 Laser and Plasma Resection will be available in the ³ÉÈËBÕ¾ booth. These sessions will be offered throughout the meeting: Friday, May 3, 10:00 – 4:00 p.m., Saturday, May 4 from 9:00 a.m. – 6:00 p.m. and Sunday, May 5 from 9:00 a.m. – 4:00 p.m. CST.
The AUA 2019 Annual Meeting is at McCormick Place in Chicago. For more information, please call 1-800-848-9024 or visit us at .
# # #
About ³ÉÈËBÕ¾ Medical Systems Group
³ÉÈËBÕ¾ is a global technology leader, crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Throughout our 100-year history, ³ÉÈËBÕ¾ has focused on being true to society and making people’s lives healthier, safer and more fulfilling.
Our Medical Business works with health care professionals to combine our innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients. For more information, visit .
*Data on file at ³ÉÈËBÕ¾.